Is rimonabant a safe and effective therapy for sustained weight loss and improved cardiometabolic risk factors?
Serena Tonstad
Original article
Nature Clinical Practice Cardiovascular Medicine (2006) 3: 364–365 [doi: 10.1038/ncpcardio0598] Article
In the July 2006 issue, the third paragraph, line 14 of the Commentary was published as "Furthermore, because of loss of randomization some of the effects of rimonabant on lipid levels, insulin and homeostasis model assessments, which were twice that expected as a result of weight loss alone, have also been shown with other drugs.4 Statistical analyses alone cannot show that anti-obesity therapy improves a patient's risk factor profile beyond weight loss". This should have appeared as "Furthermore, some of the effects of rimonabant on lipid levels, insulin and homeostasis model assessments, which were twice that expected as a result of weight loss alone, have also been shown with other drugs.4 Statistical analyses alone cannot show that anti-obesity therapy improves a patient's risk factor profile beyond weight loss because of loss of randomization."
Contact the journal about this article
